Biodesix, Inc. filings document the public reporting of a Nasdaq-listed diagnostics company with common stock trading under BDSX. The company’s 8-K reports disclose operating and financial results for its Diagnostic Testing and Development Services activities, including revenue trends, gross margin, guidance, and related press-release exhibits.
Proxy materials cover annual meeting proposals, board and governance matters, and stockholder voting. Other material-event filings document capital-structure and security-holder matters, including the completed one-for-twenty reverse stock split, common stock listing details, Nasdaq minimum bid price compliance, and amendments to the company’s charter.
Biodesix (BDSX) Chief Commercial Officer Kieran O’Kane reported RSU vesting and a related sale on 11/10/2025. He acquired 75 shares of common stock upon RSU vesting (code M) and sold 25 shares at $7.62 to cover taxes upon vesting. Following these transactions, he directly owned 7,362 shares of common stock and held 73 RSUs.
The filing notes all figures reflect the 1-for-20 reverse stock split effective September 15, 2025. The RSUs vest in sixteen successive quarterly installments measured from February 8, 2022, subject to continued service. Prior ownership includes 309 shares purchased under the Employee Stock Purchase Plan on September 2, 2025.
Biodesix (BDSX) disclosed insider activity by its President & CEO and Director, Scott Hutton. On 11/10/2025, 611 shares of Common Stock were acquired upon RSU vesting, followed by an automatic sale of 189 shares at $7.62 to cover taxes. Following these transactions, the reporting person directly beneficially owned 37,311 shares.
The amounts reflect the one-for-twenty reverse stock split effective September 15, 2025. After the vesting event, 610 RSUs remained outstanding, with RSUs vesting in successive quarterly installments measured from February 8, 2022.
Biodesix (BDSX) reported an insider transaction by its CFO, Secretary & Treasurer, Robin Harper Cowie. On 11/10/2025, 158 shares of Common Stock were acquired upon the vesting of restricted stock units, adjusted for the one-for-twenty reverse stock split effective September 15, 2025. To cover taxes from the vesting, 50 shares were sold at $7.62. Following these transactions, the reporting person beneficially owned 13,147 shares directly.
Biodesix, Inc. (BDSX) filed its Q3 2025 10‑Q reporting higher revenue and continued losses. Revenue was $21.8 million for the quarter and $59.7 million year‑to‑date, while the quarterly net loss was $8.7 million and the nine‑month net loss was $31.3 million.
Cash and cash equivalents were $16.6 million and borrowings carried at $47.1 million. The company drew a $10.0 million Tranche C loan under its Perceptive Term Loan Facility and raised $5.0 million gross through its at‑the‑market program. Stockholders’ equity shifted to a deficit of $1.7 million.
Biodesix effected a 1‑for‑20 reverse stock split on September 15, 2025 and subsequently regained Nasdaq minimum bid price compliance. Shares outstanding were 7,955,685 as of October 28, 2025.
Biodesix, Inc. furnished an 8-K announcing its financial and operating results for the third quarter ended September 30, 2025. The details are provided in a press release attached as Exhibit 99.1 and incorporated by reference as stated. The company noted the information is furnished, not filed, under the Exchange Act.
John Patience, a director of Biodesix, Inc. (BDSX), reported receipt of 1,144 restricted stock units (RSUs) effective 09/30/2025. The filing notes a one-for-twenty reverse stock split effective 09/15/2025 and states the reported share figures have been adjusted for that split. The RSUs represent contingent rights to receive one share each and vest in three substantially equal installments on 06/30/2025, 09/30/2025, and 12/31/2025, generally subject to continued service, and have no expiration date. The report discloses indirect holdings through Patience Enterprises LP (107,664 shares), the John Patience Living Trust dated 7/23/1993 (241,480 shares), and holdings attributed to a spouse (2,649 shares). The Form is signed by Robin H. Cowie as attorney-in-fact for John Patience on 10/02/2025.
Biodesix, Inc. reported that it has regained compliance with Nasdaq’s minimum bid price requirement for continued listing on The Nasdaq Global Market. On September 26, 2025, Nasdaq notified the company that its common stock once again meets the rule that requires a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days. This notice closes the earlier deficiency matter that began when the stock traded below $1.00 for 30 consecutive business days.
Amendment No. 9 to a Schedule 13D reports that Jack W. Schuler and related entities now beneficially own 2,151,480 shares of Biodesix, Inc., representing approximately 27.0% of the outstanding common stock on a post-reverse-split basis. The filing notes a one-for-twenty reverse stock split effective September 15, 2025, and discloses recent open-market purchases by Mr. Schuler through the Jack W. Schuler Living Trust: 15,317 shares at a weighted average of $6.0437, 3,056 shares at a weighted average of $6.1695, and 142,045 shares purchased in an at-the-market offering at $7.04 per share for an aggregate of $999,996.80. The source of funds for these purchases was Mr. Schuler's personal funds. Beneficial ownership includes options and vested RSUs exercisable/settling within 60 days totaling 20,735 shares; 1,380,745 shares are held by the Trust and 750,000 by a GRAT, with voting and dispositive powers shared accordingly.
Amendment No. 9 to a Schedule 13D reports that Jack W. Schuler and related entities now beneficially own 2,151,480 shares of Biodesix, Inc., representing approximately 27.0% of the outstanding common stock on a post-reverse-split basis. The filing notes a one-for-twenty reverse stock split effective September 15, 2025, and discloses recent open-market purchases by Mr. Schuler through the Jack W. Schuler Living Trust: 15,317 shares at a weighted average of $6.0437, 3,056 shares at a weighted average of $6.1695, and 142,045 shares purchased in an at-the-market offering at $7.04 per share for an aggregate of $999,996.80. The source of funds for these purchases was Mr. Schuler's personal funds. Beneficial ownership includes options and vested RSUs exercisable/settling within 60 days totaling 20,735 shares; 1,380,745 shares are held by the Trust and 750,000 by a GRAT, with voting and dispositive powers shared accordingly.
Amendment No. 9 to a Schedule 13D reports that Jack W. Schuler and related entities now beneficially own 2,151,480 shares of Biodesix, Inc., representing approximately 27.0% of the outstanding common stock on a post-reverse-split basis. The filing notes a one-for-twenty reverse stock split effective September 15, 2025, and discloses recent open-market purchases by Mr. Schuler through the Jack W. Schuler Living Trust: 15,317 shares at a weighted average of $6.0437, 3,056 shares at a weighted average of $6.1695, and 142,045 shares purchased in an at-the-market offering at $7.04 per share for an aggregate of $999,996.80. The source of funds for these purchases was Mr. Schuler's personal funds. Beneficial ownership includes options and vested RSUs exercisable/settling within 60 days totaling 20,735 shares; 1,380,745 shares are held by the Trust and 750,000 by a GRAT, with voting and dispositive powers shared accordingly.
Amendment No. 9 to a Schedule 13D reports that Jack W. Schuler and related entities now beneficially own 2,151,480 shares of Biodesix, Inc., representing approximately 27.0% of the outstanding common stock on a post-reverse-split basis. The filing notes a one-for-twenty reverse stock split effective September 15, 2025, and discloses recent open-market purchases by Mr. Schuler through the Jack W. Schuler Living Trust: 15,317 shares at a weighted average of $6.0437, 3,056 shares at a weighted average of $6.1695, and 142,045 shares purchased in an at-the-market offering at $7.04 per share for an aggregate of $999,996.80. The source of funds for these purchases was Mr. Schuler's personal funds. Beneficial ownership includes options and vested RSUs exercisable/settling within 60 days totaling 20,735 shares; 1,380,745 shares are held by the Trust and 750,000 by a GRAT, with voting and dispositive powers shared accordingly.
Amendment No. 9 to a Schedule 13D reports that Jack W. Schuler and related entities now beneficially own 2,151,480 shares of Biodesix, Inc., representing approximately 27.0% of the outstanding common stock on a post-reverse-split basis. The filing notes a one-for-twenty reverse stock split effective September 15, 2025, and discloses recent open-market purchases by Mr. Schuler through the Jack W. Schuler Living Trust: 15,317 shares at a weighted average of $6.0437, 3,056 shares at a weighted average of $6.1695, and 142,045 shares purchased in an at-the-market offering at $7.04 per share for an aggregate of $999,996.80. The source of funds for these purchases was Mr. Schuler's personal funds. Beneficial ownership includes options and vested RSUs exercisable/settling within 60 days totaling 20,735 shares; 1,380,745 shares are held by the Trust and 750,000 by a GRAT, with voting and dispositive powers shared accordingly.
Jack W. Schuler, a director and greater-than-10% owner of Biodesix, purchased 142,045 shares of Biodesix Inc. (BDSX) on 09/19/2025 at a price of $7.04 per share. After the purchase, Mr. Schuler beneficially owns 1,380,745 shares indirectly through the Jack W. Schuler Living Trust and holds an additional 750,000 shares indirectly via the Jack W. Schuler 2025 GRAT. The Form 4 was signed by an attorney-in-fact on 09/23/2025. The filing shows no derivative transactions and indicates Mr. Schuler is sole trustee of both the Living Trust and the 2025 GRAT.
Jack W. Schuler, a director and greater-than-10% owner of Biodesix, purchased 142,045 shares of Biodesix Inc. (BDSX) on 09/19/2025 at a price of $7.04 per share. After the purchase, Mr. Schuler beneficially owns 1,380,745 shares indirectly through the Jack W. Schuler Living Trust and holds an additional 750,000 shares indirectly via the Jack W. Schuler 2025 GRAT. The Form 4 was signed by an attorney-in-fact on 09/23/2025. The filing shows no derivative transactions and indicates Mr. Schuler is sole trustee of both the Living Trust and the 2025 GRAT.
Jack W. Schuler, a director and greater-than-10% holder of Biodesix, reported purchases of the issuer's common stock in two transactions. He acquired 15,317 shares at a weighted average price of $6.0437 and 3,056 shares at a weighted average price of $6.1695, increasing reported beneficial ownership to 1,238,700 shares when combining holdings attributed to the Jack W. Schuler Living Trust and other indirect vehicles.
The filing states these amounts were adjusted for a one-for-twenty reverse stock split and discloses an additional 750,000 shares held indirectly in the Jack W. Schuler 2025 GRAT. The transaction footnotes note purchases occurred at varying prices within disclosed ranges; the reporting was signed by an attorney-in-fact.
Jack W. Schuler, a director and greater-than-10% holder of Biodesix, reported purchases of the issuer's common stock in two transactions. He acquired 15,317 shares at a weighted average price of $6.0437 and 3,056 shares at a weighted average price of $6.1695, increasing reported beneficial ownership to 1,238,700 shares when combining holdings attributed to the Jack W. Schuler Living Trust and other indirect vehicles.
The filing states these amounts were adjusted for a one-for-twenty reverse stock split and discloses an additional 750,000 shares held indirectly in the Jack W. Schuler 2025 GRAT. The transaction footnotes note purchases occurred at varying prices within disclosed ranges; the reporting was signed by an attorney-in-fact.